Lead Product(s) : VNA-318
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Innosuisse
Deal Size : $2.9 million
Deal Type : Financing
Vandria Awarded €3.8M in Innosuisse and Eurostars Grants for CNS and Muscle Disease Drugs
Details : Through financing, Vandria will focus on the development of lead CNS mitophagy drug candidate VNA-318, which has the potential to treat cognitive impairment, dementia, Alzheimer’s, and Parkinson’s.
Product Name : VNA-318
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 02, 2024
Lead Product(s) : VNA-318
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Innosuisse
Deal Size : $2.9 million
Deal Type : Financing
Lead Product(s) : VNA-318
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : ND Capital
Deal Size : $20.6 million
Deal Type : Series A Financing
Details : The net proceeds will be used to develop first-in-class small molecule mitophagy inducers, including VNA-318, against a novel target to rejuvenate cells and treat age-related and chronic diseases.
Product Name : VNA-318
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2023
Lead Product(s) : VNA-318
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : ND Capital
Deal Size : $20.6 million
Deal Type : Series A Financing
Lead Product(s) : ANK-700
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).
Product Name : ANK-700
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2020
Lead Product(s) : ANK-700
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable